OPT - Opthea names seasoned pharmaceutical executive Dr. Joel Naor as CMO

Opthea (NASDAQ:OPT) has appointed Dr. Joel Naor as Chief Medical Officer, effective 1 March 2022. Dr. Naor is an ophthalmologist and seasoned pharmaceutical executive with extensive clinical program development experience from public and private companies in the ophthalmology space. In his most recent role, he served as Vice President of Clinical Science and Development Operations at Kodiak Sciences Inc. Key appointment as Opthea (OPT) progresses the Phase 3 clinical development of OPT-302 in wet AMD.

For further details see:

Opthea names seasoned pharmaceutical executive Dr. Joel Naor as CMO